Source:http://linkedlifedata.com/resource/umls/id/C0935902
NCI: A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs).,NCI: A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.,PDQ: A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. BMS-275291 selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38088&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38088&idtype=1&closed=1" closed clinical trials using this agent. ("http